FLT3 and acute myeloid leukemia: The emergence of additional TKD mutations in FLT3-ITD AML patients (FLT3-ITD-TKD) represents an important mechanism of resistance following use of TKIs [31,34,72,73,74], leading to a very poor prognosis.